Meropenem/Tazobactam

美洛培南/他唑巴坦

Report date: 2022/01/14 13:23:58

Base Information

Drug NameMeropenem/Tazobactam
Drug Alias Name他唑巴坦+美洛培南Tazobactam+meropenem他唑巴坦/美洛培南Tazobactam/meropenemMeropenem+tazobactam +[6] 
ClassificationSmall molecules > Heterocyclic drugs > AntibioticsSmall molecules > Heterocyclic drugs > Antibiotics > β-lactam antibiotics > Carbapenems antibiotics
Mechanisms of ActionBeta Lactamase inhibitorsBacterial penicillin-binding protein inhibitors
TargetsBeta LactamaseBacterial penicillin-binding protein
Therapy Area/IndicationsGram-Negative Bacterial Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes MeropenemTazobactam Sodium
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAqua Vitoe Laboratories
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAqua Vitoe Laboratories
Active IndicationsN/A
Inactive IndicationsGram-Negative Bacterial Infections

Other Information

ATC CodeN/A
Related LinksN/A